This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of the Evoque Tricuspid Valve Replacement System (Edwards Lifesciences Corp.) to treat patients with severe (or greater) tricuspid regurgitation (TR) despite optimal medical therapy who are not candidates for transcatheter repair or open heart surgery and have a poor prognosis.
